{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:45:55Z","timestamp":1777891555516,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NRE"],"published-print":{"date-parts":[[2022,1,31]]},"abstract":"<jats:p>BACKGROUND: Spasticity is common in cerebral palsy and can result in pain and diminished health-related quality of life. OBJECTIVE: To evaluate the safety and efficacy of onabotulinumtoxinA for lower limb spasticity treatment in children with cerebral palsy. METHODS: In this registrational phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT01603628), children (2\u2013&lt;\u200a17 years) with cerebral palsy and ankle spasticity (Modified Ashworth Scale-Bohannon [MAS] score\u22652) were randomized 1\u200a:\u200a1\u200a:\u200a1 to standardized physical therapy and onabotulinumtoxinA (4 or 8\u200aU\/kg), or placebo. Primary endpoint was average change from baseline at weeks 4 and 6 in MAS ankle score. Secondary endpoints included the Modified Tardieu Scale (MTS) and Global Attainment Scale (GAS). RESULTS: 381 participants were randomized. MAS scores averaged at weeks 4 and 6 were significantly reduced with both onabotulinumtoxinA doses (8\u200aU\/kg: \u20131.06, p\u200a=\u200a0.010; 4\u200aU\/kg: \u20131.01, p\u200a=\u200a0.033) versus placebo (\u20130.8). Significant improvements in average dynamic component of spasticity, measured by MTS, and in function, measured by GAS, were observed at several time points with both onabotulinumtoxinA doses versus placebo. Most adverse events were mild or moderate. CONCLUSIONS: OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children.<\/jats:p>","DOI":"10.3233\/nre-210070","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T13:04:35Z","timestamp":1640091875000},"page":"33-46","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial"],"prefix":"10.1177","volume":"50","author":[{"given":"Rozalina","family":"Dimitrova","sequence":"first","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heakyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Meilahn","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Health System, Marshfield, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry G.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital, San Diego, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad A.","family":"Racette","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis, MO, USA"},{"name":"School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Parktown, SouthAfrica"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Bonikowski","sequence":"additional","affiliation":[{"name":"Mazovian Neuropsychiatry Center, Zag\u00f3rze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sook","family":"Park","sequence":"additional","affiliation":[{"name":"Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"McCusker","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Madison, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan, an AbbVie company, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/NRE-210070_ref3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1542\/peds.2007-0854","article-title":"Parent-reported quality of life of children with cerebral palsy in Europe","volume":"121","author":"Arnaud,","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.3233\/NRE-210070_ref4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtumed.2012.12.004","article-title":"Spasticity in children","volume":"7","author":"Awaad,","year":"2012","journal-title":"Taibah University Medical Sciences"},{"issue":"8","key":"10.3233\/NRE-210070_ref5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1017\/S001216220500112X","article-title":"Proposed definition and classification of cerebral palsy, April","volume":"47","author":"Bax,","year":"2005","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"10","key":"10.3233\/NRE-210070_ref6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1469-8749.2007.00751.x","article-title":"The natural history of gross motor development in children with cerebral palsy aged to years","volume":"49","author":"Beckung,","year":"2007","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"2","key":"10.3233\/NRE-210070_ref8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon,","year":"1987","journal-title":"Physical Therapy"},{"issue":"S4","key":"10.3233\/NRE-210070_ref9","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1111\/j.1468-1331.1999.tb00031.x","article-title":"Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy","volume":"6","author":"Boyd,","year":"1999","journal-title":"European Journal of Neurology"},{"issue":"1","key":"10.3233\/NRE-210070_ref10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/S0004-282X2009000100016","article-title":"Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy","volume":"67","author":"Camargo,","year":"2009","journal-title":"Arquivos de Neuro-psiquiatria"},{"issue":"2","key":"10.3233\/NRE-210070_ref11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5535\/arm.2018.42.2.277","article-title":"Determinants of hip and femoral deformities in children with spastic cerebral palsy","volume":"42","author":"Cho,","year":"2018","journal-title":"Annals of Rehabilitation Medicine"},{"issue":"1","key":"10.3233\/NRE-210070_ref12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/dmcn.12268","article-title":"Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning \u2013Autism and Developmental Disabilities Monitoring Network, USA","volume":"56","author":"Christensen,","year":"2014","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"1","key":"10.3233\/NRE-210070_ref13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/09638288309166938","article-title":"Evaluation of rehabilitation services: the use of goal attainment scaling","volume":"5","author":"Clark,","year":"1983","journal-title":"International Rehabilitation Medicine"},{"issue":"5","key":"10.3233\/NRE-210070_ref14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pediatrneurol.2010.12.001","article-title":"Effective results with botulinumtoxin in cerebral palsy","volume":"44","author":"Coutinho dos Santos,","year":"2011","journal-title":"Pediatric Neurolology"},{"issue":"4","key":"10.3233\/NRE-210070_ref15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.0b013e3181cbcd2f","article-title":"Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society","volume":"74","author":"Delgado,","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/NRE-210070_ref16","doi-asserted-by":"crossref","first-page":"20152830","DOI":"10.1542\/peds.2015-2830","article-title":"AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial","volume":"137","author":"Delgado,","year":"2016","journal-title":"Pediatrics"},{"issue":"10","key":"10.3233\/NRE-210070_ref17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.pmrj.2017.02.014","article-title":"OnabotulinumtoxinA for lower limb spasticity: guidance from a Delphi Panel approach","volume":"9","author":"Esquenazi,","year":"2017","journal-title":"PM& R: The Journal of Injury, Function, and Rehabilitation"},{"issue":"4","key":"10.3233\/NRE-210070_ref18","first-page":"310","article-title":"Manual ability andmanual dexterity in children with cerebral palsy","volume":"18","author":"Golubovic,","year":"2014","journal-title":"Hippokratia"},{"issue":"Suppl 4","key":"10.3233\/NRE-210070_ref20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1469-8749.2009.03428.x","article-title":"Cerebral palsy and aging","volume":"51","author":"Haak,","year":"2009","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"10.3233\/NRE-210070_ref21","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00415-010-5526-3","article-title":"Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial","volume":"257","author":"Kaji,","year":"2010","journal-title":"J Neurol"},{"issue":"8","key":"10.3233\/NRE-210070_ref22","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1185\/03007995.2010.497103","article-title":"Botulinum toxin type A in post-stroke upper limb spasticity","volume":"26","author":"Kaji,","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.3233\/NRE-210070_ref23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1589\/jpts.28.1696","article-title":"The effect of postural control and balance on femoral anteversion in children with spastic cerebral palsy","volume":"28","author":"Karabicak,","year":"2016","journal-title":"Journal of Physical Therapy Science"},{"issue":"3","key":"10.3233\/NRE-210070_ref24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01241398-199405000-00005","article-title":"Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial","volume":"14","author":"Koman,","year":"1994","journal-title":"Journal of Pediatric Orthopedics"},{"key":"10.3233\/NRE-210070_ref25","unstructured":"Lance, J. W. (1980) Symposium synopsis. In R. G. Feldman, R. R. Young, &W. P. Koella (Eds.), Spasticity: disordered motor control (pp. 485\u2013495). Year Book Medical Publishers."},{"issue":"5","key":"10.3233\/NRE-210070_ref26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/mus.20059","article-title":"Structural and functional changes in spastic skeletal muscle","volume":"29","author":"Lieber,","year":"2004","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.3233\/NRE-210070_ref28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11832-010-0246-x","article-title":"The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb","volume":"4","author":"Molenaers,","year":"2010","journal-title":"Journal of Children\u2019s Orthopaedics"},{"issue":"9","key":"10.3233\/NRE-210070_ref29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1469-8749.2004.tb01021.x","article-title":"Motor impairments in young children with cerebral palsy: relationship to gross motor function and everyday activities","volume":"46","author":"Ostensj\u00f8,","year":"2004","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"3","key":"10.3233\/NRE-210070_ref30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1651-2227.2009.01626.x","article-title":"Pain in children with cerebral palsy: a cross-sectional multicentre European study","volume":"99","author":"Parkinson,","year":"2010","journal-title":"Acta Paediatrica"},{"issue":"3","key":"10.3233\/NRE-210070_ref31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01241398-200305000-00005","article-title":"Edinburgh visual gait score for use in cerebral palsy","volume":"23","author":"Read,","year":"2003","journal-title":"Journal of Pediatric Orthopedics"},{"issue":"3","key":"10.3233\/NRE-210070_ref32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1469-8749.2010.03844.x","article-title":"Distribution of motor types in cerebral palsy: how do registry data compare?","volume":"53","author":"Reid,","year":"2011","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"4","key":"10.3233\/NRE-210070_ref33","first-page":"345","article-title":"Management of spasticity in children with cerebral palsy","volume":"24","author":"Shamsoddini,","year":"2014","journal-title":"Iranian Journal of Pediatrics"},{"issue":"5","key":"10.3233\/NRE-210070_ref34","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3390\/toxins7051629","article-title":"Best clinical practice in botulinum toxin treatment for children with cerebral palsy","volume":"7","author":"Strobl,","year":"2015","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.3233\/NRE-210070_ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0966-6362(99)00012-0","article-title":"Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy","volume":"10","author":"Sutherland,","year":"1999","journal-title":"Gait &Posture"},{"issue":"3","key":"10.3233\/NRE-210070_ref36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1542\/peds.2007-1270","article-title":"Prevalence of cerebral palsy in -year-old children in three areas of the United States in: a multisite collaboration","volume":"121","author":"Yeargin-Allsopp,","year":"2008","journal-title":"Pediatrics"}],"container-title":["NeuroRehabilitation"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/NRE-210070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:06:11Z","timestamp":1777615571000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/NRE-210070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":31,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/nre-210070","relation":{},"ISSN":["1053-8135","1878-6448"],"issn-type":[{"value":"1053-8135","type":"print"},{"value":"1878-6448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]}}}